270 related articles for article (PubMed ID: 35295900)
1. Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum.
Kaura A; Trickey A; Shah ASV; Benedetto U; Glampson B; Mulla A; Mercuri L; Gautama S; Costelloe CE; Goodman I; Redhead J; Saravanakumar K; Mayer E; Mayet J
EClinicalMedicine; 2022 Apr; 46():101344. PubMed ID: 35295900
[TBL] [Abstract][Full Text] [Related]
2. Assessing COVID-19 Vaccine Uptake and Effectiveness Through the North West London Vaccination Program: Retrospective Cohort Study.
Glampson B; Brittain J; Kaura A; Mulla A; Mercuri L; Brett SJ; Aylin P; Sandall T; Goodman I; Redhead J; Saravanakumar K; Mayer EK
JMIR Public Health Surveill; 2021 Sep; 7(9):e30010. PubMed ID: 34265740
[TBL] [Abstract][Full Text] [Related]
3. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
Rosero-Bixby L
JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
[TBL] [Abstract][Full Text] [Related]
4. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
[TBL] [Abstract][Full Text] [Related]
7. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of single and two-dose Pfizer-BioNTech vaccine against SARS-COV-2: A real-world evidence from Saudi Arabia.
Albogami Y; Alalwan A; Batais MA; Alabdulkareem K; Alalwan AA
J Infect Public Health; 2023 Dec; 16(12):1898-1903. PubMed ID: 37871358
[TBL] [Abstract][Full Text] [Related]
9. The Effect of COVID-19 Vaccines on Hospital Admission and Severity of Symptoms Among COVID-19 Patients in Saudi Arabia, 2021.
Alnemari RF; Roublah FA; Bargawi AA
Cureus; 2023 Jun; 15(6):e41067. PubMed ID: 37519611
[TBL] [Abstract][Full Text] [Related]
10. Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study.
Aldali J; Meo SA; Al-Khlaiwi T
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851109
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
12. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
Yürüker Ö; Yetkin O; Güvenir M
Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
[TBL] [Abstract][Full Text] [Related]
13. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
14. Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland.
Anderegg N; Althaus CL; Colin S; Hauser A; Laube A; Mäusezahl M; Wagner M; Zaffora B; Riou J
Swiss Med Wkly; 2022 Apr; 152():w30163. PubMed ID: 35752951
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
16. Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia.
AlRuthia Y; Al-Salloum HF; Almohammed OA; Alqahtani AS; Al-Abdulkarim HA; Alsofayan YM; Almudarra SS; AlQahtani SH; Almutlaq A; Alabdulkareem K; Balkhi B; Almutairi HT; Alanazi AS; Asiri YA
Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214781
[TBL] [Abstract][Full Text] [Related]
17. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
[TBL] [Abstract][Full Text] [Related]
18. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
[TBL] [Abstract][Full Text] [Related]
19. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
[TBL] [Abstract][Full Text] [Related]
20. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]